Metronidazole B. Braun (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced by intracellular electron‑transfer proteins. This reduction creates reactive nitro radical anions that damage DNA, inhibit nucleic acid synthesis, and ultimately lead to cell death. The drug’s activation is selective for low‑oxygen organisms, sparing most aerobic cells.

The dosage of Metronidazole B. Braun is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate dose and infusion rate for each individual case.

Metronidazole is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no well‑controlled human studies. It may be used during pregnancy when the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so clinicians should weigh benefits against possible exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details—including any cold‑chain requirements—and required import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering rapid bactericidal activity. Compared with broad‑spectrum agents like clindamycin or beta‑lactams, metronidazole provides a narrower spectrum focused on anaerobes, often with fewer drug‑interaction concerns. Choice of therapy depends on infection type, susceptibility patterns, and patient factors.

Metronidazole B. Braun should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used within the time frame specified by the manufacturer, but refrigeration should be restored promptly.

Metronidazole B. Braun is administered intravenously by a healthcare professional. The drug is supplied as a sterile solution for injection and is typically infused over a prescribed period, often 30‑60 minutes, depending on the clinical protocol. Proper aseptic technique and infusion equipment are required to ensure safe delivery.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as Stevens‑Johnson syndrome, and hepatotoxicity. Patients should be monitored for neurological symptoms, skin changes, and liver function abnormalities. Prompt medical attention is required if any severe or unexpected reactions occur during treatment.

Metronidazole B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for individuals with severe hepatic impairment, those receiving disulfiram, and patients with a history of seizures unless the benefits outweigh the risks.